ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc to Host Investor Event and Webcast From Clinical Trials on Alzheimer's Disease (CTAD) Meeting Transcript

Dec 05, 2019 / 03:15AM GMT
Release Date Price: $50.48 (+14.00%)
Mark C. Johnson
ACADIA Pharmaceuticals Inc. - VP of IR

All right. Good evening, everyone. I think we're ready to start. Thank you for joining us tonight to discuss the top line results from the Phase III HARMONY study in dementia-related psychosis, or DRP. I'd like to point out that we are using supplemental slides, which are available on the Events & Presentations section of our IR website.

First, tonight, we will hear from Steve Davis, our Chief Executive Officer, who will provide a few opening remarks; and then turn it over to Erin Foff, the clinical lead for our DRP program, who just presented at the 12th Annual Clinical Trials of Alzheimer's Disease Meeting these exciting results. Following Erin's presentation, Serge Stankovic, our President, will make a few remarks on our next steps for DRP. And then we will transition to a KOL panel to discuss with a Q&A.

I'm extremely pleased to introduce our 3 panelists this evening: Dr. Jeff Cummings, a research professor from the Department of Brain Health at UNLV and Director Emeritus at the Cleveland Clinic Lou Ruvo Center for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot